FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib (Q46124285)

From Wikidata

Jump to navigation Jump to search

scientific article published on 12 February 2009

Language	Label	Description	Also known as
English	FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib	scientific article published on 12 February 2009

Statements

scholarly article

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19212337

FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib (English)

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19212337

1 reference

based on heuristic

inferred from title

eosinophilic leukemia

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19212337

Peter Vandenberghe

7

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19212337

author name string

E Lierman

1

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19212337

L Michaux

2

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19212337

E Beullens

3

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19212337

P Pierre

4

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19212337

P Marynen

5

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19212337

language of work or name

1 reference

based on heuristic

inferred from title

publication date

12 February 2009

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19212337

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19212337

23

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19212337

5

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19212337

845-851

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19212337

https://scigraph.springernature.com/pub.10.1038/leu.2009.2

0 references

Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

21 January 2018

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

7 January 2021

based on heuristic

inferred from DOI database lookup

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic eosinophilic leukaemia with FIP1L1-PDGFRA fusion and T6741 mutation that evolved from Langerhans cell histiocytosis with eosinophilia after chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

7 January 2021

based on heuristic

inferred from DOI database lookup

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

7 January 2021

based on heuristic

inferred from DOI database lookup

The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

7 January 2021

based on heuristic

inferred from DOI database lookup

The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib for the treatment of advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Tyrosine kinases as targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

7 January 2021

based on heuristic

inferred from DOI database lookup

The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

7 January 2021

based on heuristic

inferred from DOI database lookup

FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2009.2

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19212337

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19212337

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46124285&oldid=2093832070"